Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 3Phase 2/3 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 158Other hematologic neoplasm 104Breast 56Gastrointestinal 46Plasma cell 38Dermatologic 37Gynecologic 33Myeloid 23Genitourinary 22Thoracic 20Sarcoma 18Other solid neoplasm 17Classical hematology 11CNS 11Head & Neck 10Tumor-Agnostic 5Other neoplasm 1

Conditions

Non-Malignant Neoplasm 1

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Docetaxel 2thymoglobulin 1ruxolitinib 1fludarabine 1alethine 1Stem Cell Transplantation 1Sirolimus 1Phenytoin 1Methotrexate 1Irinotecan 1Infusions, Intravenous 1Ifosfamide 1High-Intensity Focused Ultrasound Ablation 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Endoscopy, Digestive System 1Endoscopy 1Cyclosporine 1Cyclophosphamide 1Celecoxib 1Carboplatin 1CPI-0610 1Busulfan 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cyclophosphamide × Other neoplasm × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡